<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0420</journal-id>
<journal-title><![CDATA[Revista Uruguaya de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Urug.Cardiol.]]></abbrev-journal-title>
<issn>1688-0420</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Uruguaya de Cardiología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-04202025000101402</article-id>
<article-id pub-id-type="doi">10.29277/cardio.40.1.11</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Lo mejor del Congreso ACC 2025]]></article-title>
<article-title xml:lang="en"><![CDATA[The best of ACC Congress 2025]]></article-title>
<article-title xml:lang="pt"><![CDATA[O melhor do Congresso ACC 2025]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Olivera Sosa]]></surname>
<given-names><![CDATA[Jessica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Dirección Nacional de Sanidad de las Fuerzas Armadas  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<volume>40</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-04202025000101402&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-04202025000101402&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-04202025000101402&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El Congreso Anual del Colegio Americano de Cardiología (American College of Cardiology, ACC) se celebró en Chicago (Estados Unidos), del 29 al 31 de marzo de 2025. Este evento tan esperado reunió a profesionales de todo el mundo, con sesiones que abordaron diversos tópicos, incluyendo innovaciones terapéuticas, tecnologías de vanguardia, entre otros. Fueron presentados varios ensayos clínicos de gran calidad científica y con potencial impacto en la práctica clínica. A continuación, resumimos y discutimos los resultados principales que arrojaron cinco de los ensayos presentados en el Congreso, seleccionados por su gran relevancia clínica.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract The American College of Cardiology (ACC) Annual Meeting was held in Chicago (USA), from March 29 to 31, 2025. This highly anticipated event brought together professionals from around the world, with sessions covering a wide range of topics, including therapeutic innovations and cutting-edge technologies. Several high-quality clinical trials with the potential to impact clinical practice were presented. Below, we summarize and discuss the main results of five of these trials, selected for their significant clinical relevance.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo A Reunião Anual do Colégio Americano de Cardiologia (ACC) foi realizada em Chicago (EUA), de 29 a 31 de março de 2025. Este evento tão aguardado reuniu profissionais de todo o mundo, com sessões que abordaram uma ampla variedade de tópicos, incluindo inovações terapêuticas e tecnologias de ponta. Diversos ensaios clínicos de alta qualidade científica e com potencial impacto na prática clínica foram apresentados. A seguir, resumimos e discutimos os principais resultados de cinco desses ensaios apresentados na reunião, selecionados por sua significativa relevância clínica.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[RIVAWAR]]></kwd>
<kwd lng="es"><![CDATA[API-CAT]]></kwd>
<kwd lng="es"><![CDATA[FRESH UP]]></kwd>
<kwd lng="es"><![CDATA[BHF PROTECT-TAVI]]></kwd>
<kwd lng="es"><![CDATA[FAME 3]]></kwd>
<kwd lng="en"><![CDATA[RIVAWAR]]></kwd>
<kwd lng="en"><![CDATA[API-CAT]]></kwd>
<kwd lng="en"><![CDATA[FRESH UP BHF PROTECT-TAVI]]></kwd>
<kwd lng="en"><![CDATA[FAME 3]]></kwd>
<kwd lng="pt"><![CDATA[RIVAWAR]]></kwd>
<kwd lng="pt"><![CDATA[API-CAT]]></kwd>
<kwd lng="pt"><![CDATA[FRESH UP]]></kwd>
<kwd lng="pt"><![CDATA[BHF PROTECT-TAVI]]></kwd>
<kwd lng="pt"><![CDATA[FAME 3]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camaj]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fuster]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Giustino]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bienstock]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sternheim]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mehran]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Dangas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Left ventricular thrombus following acute myocardial infarction JACC state-of-the-art review]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2022</year>
<volume>79</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1010-22</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<source><![CDATA[Rivaroxaban comparable to warfarin in left ventricular blood clots]]></source>
<year>2025</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mazzolai]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Adriano]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Treatment of cancer-associated venous thromboembolism]]></source>
<year>2025</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahé]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Carrier]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mayeur]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Chidiac]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vicaut]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Falvo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Extended reduced-dose apixaban for cancer-associated venous thromboembolism]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2025</year>
<volume>392</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1363-73</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Warraich]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Sá]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jacquemyn]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Kuno]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Serna-Gallegos]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sultan]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cerebral embolic protection devices in transcatheter aortic valve implantation meta-analysis with trial sequential analysis]]></article-title>
<source><![CDATA[J Am Heart Assoc]]></source>
<year>2025</year>
<volume>14</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kharbanda]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kennedy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jamal]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Dodd]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bal]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Routine cerebral embolic protection during transcatheter aortic-valve implantation]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2025</year>
<volume>392</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>2403-12</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Serruys]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Morice]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kappetein]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Colombo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Holmes]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mack]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2009</year>
<volume>360</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>961-72</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fearon]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Zimmermann]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[De Bruyne]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Piroth]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[van Straten]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Szekely]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fractional flow reserve-guided PCI as compared with coronary bypass surgery]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2022</year>
<volume>386</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>128-37</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zimmermann]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ding]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Pijls]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Piroth]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[van Straten]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Szekely]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Davidavicius]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[FAME 3 Investigators Fractional flow reserve-guided pci or coronary bypass surgery for 3-vessel coronary artery disease: 3-year follow-up of the FAME 3 trial]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2023</year>
<volume>148</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>950-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fearon]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Zimmermann]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ding]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Takahashi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Piroth]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[van Straten]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3) 5-year follow-up of a multicentre, open-label, randomised trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2025</year>
<volume>405</volume>
<numero>10488</numero>
<issue>10488</issue>
<page-range>1481-90</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cox]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
</person-group>
<source><![CDATA[PCI rebounds at 5 years to mostly match CABG: Final FAME 3 data]]></source>
<year>2025</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
